[go: up one dir, main page]

HU211667A9 - Apolipoprotein - Google Patents

Apolipoprotein Download PDF

Info

Publication number
HU211667A9
HU211667A9 HU95P/P00630P HU9500630P HU211667A9 HU 211667 A9 HU211667 A9 HU 211667A9 HU 9500630 P HU9500630 P HU 9500630P HU 211667 A9 HU211667 A9 HU 211667A9
Authority
HU
Hungary
Prior art keywords
dimer
apo
apolipoprotein
milano
pharmaceutical composition
Prior art date
Application number
HU95P/P00630P
Other languages
English (en)
Inventor
Peter Lind
Erik Holmgren
Mats Lake
Bjoern Nilsson
Lars Abrahmsen
Cesare Sirtori
Guido Franceschini
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of HU211667A9 publication Critical patent/HU211667A9/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (17)

1. Apolipoprotein-Al-Milano dimer, lényegében tiszta formában.
2. Az 1. igénypont szerinti Apolipoprotein-Al-Milano dimer, amely vérplazmából származik.
3. Apolipoprotein-Al-Milano dimer, amely lényegében megegyezik az 1. vagy 2. példában leírt és bemutatott Apolipoprotein-Al-Milano dimerekkel.
4. Az 1, igénypont szerinti Apolipoprotein-Al-Milano dimer, amely rekombináns eljárással van előállítva.
5. Apolipoprotein-Al-Milano dimer, amely lényegében megegyezik a 3. példában leírt és bemutatott Apolipoprotein-Al-Milano dimerrel.
6. Gyógyászati készítmény, amely az 1. igénypont szerinti dimert hordozóval együtt tartalmazza.
7. Gyógyászati készítmény, amely az 1. igénypont szerinti dimert stabilizáló ágenssel és adott esetben hordozóval együtt tartalmazza.
8. Az 6. vagy 7. igénypont szerinti gyógyászati készítmény, amely lipid tartalom csökkentő anyagot és hordozót is tartalmaz.
9. Az 7. igénypont szerinti gyógyászati készítmény. amely a dimert egy stabilizáló lipid vegyülettel együtt tartalmazza, és adott esetben lipidtartalom csökkentő anyagot, valamint adott esetben hordozót is tartalmaz.
10. Az 6. igénypont szerinti gyógyászati készítmény, amely foszfolipidet is tartalmaz, adott esetben lipidtartalom csökkentő anyaggal és adott esetben hordozóval együtt.
11. Eljárás az 1. igénypont szerinti dimer előállítására, azzal jellemezve hogy
a) a dimert olyan rekombináns eljárással állítjuk elő, mely szerint E. coli intracelluláris fúziós fehérje rendszert, majd hangyasavas hasítást alkalmazunk,
b) a dimert vérplazmából állítjuk elő úgy, hogy Apolipoprotein-Al-Milano hordozó személyektől vérplazmát gyűjtünk, izoláljuk a HDL-apolipoproteineket és a dimert több lépésben végzett Sephacryl-kromatográfiával választjuk el,
c) a dimert vérplazmából állítjuk elő úgy, hogy először a monomert tisztítjuk, majd azt dimerré alakítjuk.
12. Az 1. igénypont szerinti dimer alkalmazása a dimert tartalmazó ateroszklerózis és más kardiovaszkuláris betegségek kezelésére alkalmas gyógyászati készítmény előállítására.
13. A 12. igénypont szerinti alkalmazás főbb szív- és érrendszeri betegségek, mint például szívizom infarktus, kiegyensúlyozatlan angina és akut perifériális érrendszeri elzáródások megelőzésére és kezelésére.
14. A 12. igénypont szerinti alkalmazás a krónikus artériás állapotok kezelésére.
15. A 12. igénypont szerinti alkalmazás trombózis megelőzésére és kezelésére.
16. A 12. igénypont szerinti alkalmazás, amelynél a gyógyászati készítmény lipidtartalom csökkentő hatóanyagot is tartalmaz.
17. Az 1. igénypont szerinti dimer alkalmazása a dimert tartalmazó, ateroszklerózis és más kardiovaszkuláris betegségek kezelésére alkalmas gyógyászati készítmény előállítására, amelynél a dimer a monomer „prodrug”-jaként hat.
HU95P/P00630P 1991-12-13 1995-06-30 Apolipoprotein HU211667A9 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103701A SE9103701D0 (sv) 1991-12-13 1991-12-13 Apolipoprotein

Publications (1)

Publication Number Publication Date
HU211667A9 true HU211667A9 (en) 1995-12-28

Family

ID=20384608

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9302344A HU217203B (hu) 1991-12-13 1992-12-11 Apolipoprotein molekuláris variánsának dimerje, és az előállítására szolgáló eljárás
HU95P/P00630P HU211667A9 (en) 1991-12-13 1995-06-30 Apolipoprotein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU9302344A HU217203B (hu) 1991-12-13 1992-12-11 Apolipoprotein molekuláris variánsának dimerje, és az előállítására szolgáló eljárás

Country Status (28)

Country Link
US (2) US5876968A (hu)
EP (1) EP0571602B1 (hu)
JP (1) JPH07502892A (hu)
AT (1) ATE242269T1 (hu)
AU (2) AU3175593A (hu)
BG (1) BG61451B1 (hu)
BR (1) BR9205640A (hu)
CA (1) CA2103996C (hu)
CZ (1) CZ289879B6 (hu)
DE (1) DE69233092T2 (hu)
DK (1) DK0571602T3 (hu)
EE (1) EE03058B1 (hu)
ES (1) ES2199939T3 (hu)
FI (1) FI115771B (hu)
HU (2) HU217203B (hu)
IL (1) IL103956A (hu)
MX (1) MX9207224A (hu)
NO (1) NO315076B1 (hu)
NZ (2) NZ246223A (hu)
PL (3) PL171907B1 (hu)
PT (1) PT571602E (hu)
RO (1) RO115636B1 (hu)
RU (1) RU2134696C1 (hu)
SE (1) SE9103701D0 (hu)
SG (1) SG47453A1 (hu)
SK (1) SK86893A3 (hu)
WO (1) WO1993012143A1 (hu)
ZA (1) ZA928989B (hu)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
DK1290013T3 (da) * 2000-04-21 2006-06-26 Amgen Inc Apo-A1/All-peptidderivater
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
AU2002213843B2 (en) * 2000-11-10 2008-02-07 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
WO2003026492A2 (en) * 2001-09-28 2003-04-03 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
AU2002360489A1 (en) * 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US20040067873A1 (en) 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
MXPA04011227A (es) * 2002-05-17 2005-01-25 Esperion Therapeutics Inc Metodos y composiciones para el tratamiento de la reperfusion isquemica.
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
WO2005051413A2 (en) * 2003-11-26 2005-06-09 Novartis Ag Disease associated genes
WO2005058938A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
EP1732383A4 (en) 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH RECOMBINANT ADENO ASSOCIATED VIRUS VECTORS THAT CODE APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US9487575B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
BRPI0610983A2 (pt) 2005-04-29 2010-08-10 Universirty Of California peptìdeos e miméticos de peptìdeos para tratar patologias caracterizadas por uma resposta inflamatória
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
KR100719389B1 (ko) 2005-10-18 2007-05-17 주식회사 녹십자 인간혈장으로부터 아포리포단백질 ａ-ｉ을 분리 정제하는방법
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US9637753B2 (en) * 2006-08-10 2017-05-02 Plantechno S.R.L. In-plant production of oligomeric (comprising three or more units) forms of human Apo A-1 protein muteins
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
US9422363B2 (en) 2007-08-28 2016-08-23 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009050266A2 (en) * 2007-10-19 2009-04-23 Pronota N.V. Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
KR20100100824A (ko) 2007-10-23 2010-09-15 더 클리브랜드 클리닉 파운데이션 산화제 내성 아포지단백질 ａ-1 및 모방체 펩티드
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
CN111909020A (zh) 2008-11-10 2020-11-10 阿布特斯生物制药公司 用于递送治疗剂的脂质和组合物
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
KR20240015723A (ko) 2009-05-05 2024-02-05 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
CA2764609C (en) 2009-06-10 2018-10-02 Alnylam Pharmaceuticals, Inc. Improved cationic lipid of formula i
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
DK2379581T3 (da) * 2009-12-14 2014-01-06 Scil Proteins Gmbh Fremgangsmåde til identifikation af hetero-multimerisk modificerede ubiquitinproteiner med evne til binding til ligander
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) * 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
ES3053320T3 (en) 2010-06-03 2026-01-21 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130142760A1 (en) 2010-08-18 2013-06-06 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
CN103443123B (zh) 2011-02-07 2020-05-29 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
WO2012172055A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
MX2014001920A (es) 2011-08-25 2014-04-14 Hoffmann La Roche Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma.
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
MX2016014306A (es) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Marcadores para terapia con lipoproteinas de alta densidad (hdl).
USRE50320E1 (en) 2014-07-31 2025-03-04 Uab Research Foundation APOE mimetic peptides and higher potency to clear plasma cholesterol
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
WO2017009421A1 (en) 2015-07-16 2017-01-19 Scil Proteins Gmbh Novel immunoglobulin-binding proteins and their use in affinity purification
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
US11813336B2 (en) 2016-05-04 2023-11-14 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CN117736281A (zh) 2016-08-11 2024-03-22 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
TW201919686A (zh) 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 脫輔基子(apomers)
EP3668600B1 (en) 2017-08-10 2024-05-15 Abionyx Pharma SA Cargomers
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
WO2020127224A1 (en) 2018-12-18 2020-06-25 Navigo Proteins Gmbh Novel folr1 specific binding proteins for cancer diagnosis and treatment
JP2023522889A (ja) 2020-04-16 2023-06-01 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法
JP2023543498A (ja) 2020-10-01 2023-10-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
CN117479834A (zh) 2021-04-15 2024-01-30 阿比奥尼克斯制药公司 基于脂质结合蛋白的复合物在器官保存溶液中的用途
IL316110A (en) 2022-04-06 2024-12-01 Abionyx Pharma Sa Methods for treating eye diseases using complexes based on fat-binding protein
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
CA3258787A1 (en) 2022-06-10 2023-12-14 Stanislas FAGUER METHODS OF TREATMENT OF HYPERINFLAMMATORY DISEASES USING LIPID-BINDING PROTEIN COMPLEXES
EP4536269A2 (en) 2022-06-10 2025-04-16 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein-based complexes
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein

Also Published As

Publication number Publication date
AU703283B2 (en) 1999-03-25
HU217203B (hu) 1999-12-28
ATE242269T1 (de) 2003-06-15
NZ280516A (en) 1997-06-24
US5876968A (en) 1999-03-02
EP0571602B1 (en) 2003-06-04
CA2103996A1 (en) 1993-06-14
BR9205640A (pt) 1994-05-03
ES2199939T3 (es) 2004-03-01
DK0571602T3 (da) 2003-10-06
SG47453A1 (en) 1998-04-17
JPH07502892A (ja) 1995-03-30
BG98036A (bg) 1994-05-27
AU5947396A (en) 1996-10-31
PL172168B1 (pl) 1997-08-29
CZ289879B6 (cs) 2002-04-17
US6617134B1 (en) 2003-09-09
RU2134696C1 (ru) 1999-08-20
CA2103996C (en) 2007-01-16
EP0571602A1 (en) 1993-12-01
CZ158993A3 (en) 1994-07-13
PL172544B1 (pl) 1997-10-31
NO315076B1 (no) 2003-07-07
NO932866L (no) 1993-08-12
HU9302344D0 (en) 1994-01-28
HUT70270A (en) 1995-09-28
SE9103701D0 (sv) 1991-12-13
ZA928989B (en) 1993-05-17
NZ246223A (en) 1996-06-25
WO1993012143A1 (en) 1993-06-24
DE69233092D1 (de) 2003-07-10
IL103956A (en) 1998-09-24
PT571602E (pt) 2003-10-31
FI115771B (fi) 2005-07-15
FI933557A0 (fi) 1993-08-12
BG61451B1 (en) 1997-08-29
DE69233092T2 (de) 2004-07-08
RO115636B1 (ro) 2000-04-28
IL103956A0 (en) 1993-05-13
FI933557L (fi) 1993-08-12
SK86893A3 (en) 1994-04-06
EE03058B1 (et) 1997-12-15
PL171907B1 (pl) 1997-06-30
AU3175593A (en) 1993-07-19
NO932866D0 (no) 1993-08-12
PL300262A1 (en) 1994-03-07
MX9207224A (es) 1993-06-01

Similar Documents

Publication Publication Date Title
HU211667A9 (en) Apolipoprotein
Bellotti et al. β 2‐microglobulin can be refolded into a native state from ex vivo amyloid fibrils
FI94876C (fi) Menetelmä aprotiniinin valmistamiseksi yhdistelmä-DNA-tekniikalla ja menetelmään soveltuva DNA, ilmentämisplasmidi ja isäntäsolu
JP3122127B2 (ja) 抗凝血タンパク質
JP4344136B2 (ja) アポリポタンパク質類似体
Vogt et al. Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E‐3M2H
EP1379266B1 (en) Modified annexin proteins and prevention and treatment of thrombosis
US7223726B2 (en) Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
JP3845101B2 (ja) ヒト・アポリポ蛋白質ａｉおよびａｉ−ミラノを含有する医薬組成物
JP2006223316A (ja) 組換えフィブリン鎖、フィブリンおよびフィブリン−ホモログ
JP2023529497A (ja) 補体因子ｉ関連組成物および方法
Nikawa et al. Studies on the reactive site of the cystatin superfamily using recombinant cystatin A mutants: Evidence that the QVVAG region is not essential for cysteine proteinase inhibitory activities
KR100486472B1 (ko) 폰빌레브란트인자의치료성단편
US7078485B2 (en) N-terminal modified recombinant human endostatin and its production
Duverger et al. Functional characterization of human recombinant apolipoprotein AIV produced in Escherichia coli
Pillot et al. Single-Step Purification of Two Functional Human Apolipoprotein E Variants Hyperexpressed inEscherichia coli
JPH04210700A (ja) 組換ヒトトロンボモジュリン誘導体
JPH10113195A (ja) 凍結乾燥製剤の製造法
JPH10113180A (ja) トロンビンによるプロテインｃの活性化を促進する作用を有するペプチドをコードするｄｎａ及びペプチドの製造法

Legal Events

Date Code Title Description
HPC4 Succession in title of patentee

Owner name: ESPERION THERAPEUTICS INC.,, US